Drugs / PMC2129G12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07587879 | Jan 2027 → Jan 2030 expected | cancer or benign tumor | IntraAb, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMC2129G12 | “PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a...” NCT07587879 ↗ |
| Modality | Messenger RNA (mRNA) | “messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy” NCT07587879 ↗ |
| Route | Other | “administered by intratumoral injection” NCT07587879 ↗ |